Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Brincidofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Emergent BioSolutions Tests Brincidofovir for Mpox Virus Safety and Efficacy in Africa
Details : Tembexa (brincidofovir) is an antiviral medical countermeasure that is part of Emergent’s product portfolio and will be evaluated for the safety and efficacy in treating mpox virus.
Brand Name : Tembexa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 06, 2024
Lead Product(s) : Brincidofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Brincidofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Biomedical Advanced Research and Development Authority
Deal Size : $374.5 million
Deal Type : Agreement
Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox
Details : Collaboration with BARDA for the development of TEMBEXA (brincidofovir) has provided the United States government with a second therapeutic option to ensure the federal government’s readiness for a potential smallpox emergency.
Brand Name : Tembexa
Molecule Type : Small molecule
Upfront Cash : $238.0 million
August 29, 2022
Lead Product(s) : Brincidofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Biomedical Advanced Research and Development Authority
Deal Size : $374.5 million
Deal Type : Agreement
Lead Product(s) : Brincidofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Public Health Agency of Canada
Deal Size : $25.3 million
Deal Type : Agreement
Details : Chimerix signed a contract agreement to procure TEMBEXA® (brincidofovir). Execution of this contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the pending transaction with Emergent BioSolution...
Brand Name : Tembexa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 24, 2022
Lead Product(s) : Brincidofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Public Health Agency of Canada
Deal Size : $25.3 million
Deal Type : Agreement
Lead Product(s) : Brincidofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Emergent BioSolutions
Deal Size : $9.3 million
Deal Type : Agreement
Chimerix Announces $9.3 Million International TEMBEXA Procurement Agreement
Details : Chimerix expects to promptly provide treatment courses of TEMBEXA (brincidofovir) equivalent to the total value of the procurement contract. Execution of this contract will be the responsibility of Chimerix.
Brand Name : Tembexa
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 23, 2022
Lead Product(s) : Brincidofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Emergent BioSolutions
Deal Size : $9.3 million
Deal Type : Agreement
Lead Product(s) : Brincidofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Emergent BioSolutions
Deal Size : $325.0 million
Deal Type : Acquisition
Details : TEMBEXA (brincidofovir), is an oral antiviral formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks. TEMBEXA is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates.
Brand Name : Tembexa
Molecule Type : Small molecule
Upfront Cash : $225.0 million
May 16, 2022
Lead Product(s) : Brincidofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Emergent BioSolutions
Deal Size : $325.0 million
Deal Type : Acquisition
Lead Product(s) : Brincidofovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 29, 2020
Lead Product(s) : Brincidofovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?